Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.

Stringer BW, Day BW, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgül S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis PL, Jeffree RL, Johns TG, Boyd AW.

Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z.

2.

EphA4 Regulates Hippocampal Neural Precursor Proliferation in the Adult Mouse Brain by d-Serine Modulation of N-Methyl-d-Aspartate Receptor Signaling.

Zhao J, Taylor CJ, Newcombe EA, Spanevello MD, O'Keeffe I, Cooper LT, Jhaveri DJ, Boyd AW, Bartlett PF.

Cereb Cortex. 2018 Dec 22. doi: 10.1093/cercor/bhy319. [Epub ahead of print]

PMID:
30590507
3.

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma.

Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs AV, Bell CA, Jeffree R, Rose S, Thurecht KJ, Boyd AW, Day BW.

Cancers (Basel). 2018 Dec 17;10(12). pii: E519. doi: 10.3390/cancers10120519.

4.

T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development.

de Bock CE, Down M, Baidya K, Sweron B, Boyd AW, Fiers M, Burns GF, Molloy TJ, Lock RB, Soulier J, Taghon T, Van Vlierberghe P, Cools J, Holst J, Thorne RF.

Haematologica. 2019 May;104(5):e204-e207. doi: 10.3324/haematol.2018.198424. Epub 2018 Dec 4. No abstract available.

5.

Extracellular Vesicles Released by Glioblastoma Cells Stimulate Normal Astrocytes to Acquire a Tumor-Supportive Phenotype Via p53 and MYC Signaling Pathways.

Hallal S, Mallawaaratchy DM, Wei H, Ebrahimkhani S, Stringer BW, Day BW, Boyd AW, Guillemin GJ, Buckland ME, Kaufman KL.

Mol Neurobiol. 2019 Jun;56(6):4566-4581. doi: 10.1007/s12035-018-1385-1. Epub 2018 Oct 23.

PMID:
30353492
6.

Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1G93A ALS mouse model.

Zhao J, Cooper LT, Boyd AW, Bartlett PF.

Sci Rep. 2018 Jul 30;8(1):11393. doi: 10.1038/s41598-018-29845-1.

7.

Eph receptors as oncotargets.

Charmsaz S, Boyd AW.

Oncotarget. 2017 Sep 19;8(47):81727-81728. doi: 10.18632/oncotarget.21045. eCollection 2017 Oct 10. No abstract available.

8.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.

Charmsaz S, Scott AM, Boyd AW.

Exp Hematol. 2017 Oct;54:31-39. doi: 10.1016/j.exphem.2017.07.003. Epub 2017 Jul 24. Review.

PMID:
28751189
9.

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

Pegg CL, Cooper LT, Zhao J, Gerometta M, Smith FM, Yeh M, Bartlett PF, Gorman JJ, Boyd AW.

Sci Rep. 2017 Jul 26;7(1):6519. doi: 10.1038/s41598-017-06685-z.

10.

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.

Gilabert-Oriol R, Furness SGB, Stringer BW, Weng A, Fuchs H, Day BW, Kourakis A, Boyd AW, Hare DL, Thakur M, Johns TG, Wookey PJ.

Cancer Immunol Immunother. 2017 Sep;66(9):1217-1228. doi: 10.1007/s00262-017-2013-z. Epub 2017 May 13.

PMID:
28501939
11.

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH.

Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.

12.

The identification of a novel isoform of EphA4 and ITS expression in SOD1G93A mice.

Zhao J, Boyd AW, Bartlett PF.

Neuroscience. 2017 Apr 7;347:11-21. doi: 10.1016/j.neuroscience.2017.01.038. Epub 2017 Jan 30.

PMID:
28153688
13.

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW.

Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6.

PMID:
27922598
14.

Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.

Stringer BW, Bunt J, Day BW, Barry G, Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S, Smith FM, Cooper LT, Piper M, Boyd AW, Richards LJ.

Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720.

15.

EPHA4-FC TREATMENT REDUCES ISCHEMIA/REPERFUSION-INDUCED INTESTINAL INJURY BY INHIBITING VASCULAR PERMEABILITY.

Woodruff TM, Wu MC, Morgan M, Bain NT, Jeanes A, Lipman J, Ting MJ, Boyd AW, Taylor SM, Coulthard MG.

Shock. 2016 Feb;45(2):184-91. doi: 10.1097/SHK.0000000000000494.

PMID:
26771935
16.

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.

Zakaria Z, Tivnan A, Flanagan L, Murray DW, Salvucci M, Stringer BW, Day BW, Boyd AW, Kögel D, Rehm M, O'Brien DF, Byrne AT, Prehn JH.

Br J Cancer. 2016 Jan 19;114(2):188-98. doi: 10.1038/bjc.2015.420. Epub 2015 Dec 10.

17.

Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis.

Manton KJ, Douglas ML, Netzel-Arnett S, Fitzpatrick DR, Nicol DL, Boyd AW, Clements JA, Antalis TM.

Br J Cancer. 2015 Dec 1;113(11):1640. doi: 10.1038/bjc.2015.384. No abstract available.

18.

EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study.

Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M, Boyd AW, Rose S.

Mol Imaging. 2015;14:385-99.

PMID:
26218510
19.

EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.

Charmsaz S, Beckett K, Smith FM, Bruedigam C, Moore AS, Al-Ejeh F, Lane SW, Boyd AW.

PLoS One. 2015 Jun 17;10(6):e0130692. doi: 10.1371/journal.pone.0130692. eCollection 2015.

20.

Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines.

Rahman M, Reyner K, Deleyrolle L, Millette S, Azari H, Day BW, Stringer BW, Boyd AW, Johns TG, Blot V, Duggal R, Reynolds BA.

Anat Cell Biol. 2015 Mar;48(1):25-35. doi: 10.5115/acb.2015.48.1.25. Epub 2015 Mar 20.

21.

Eph family co-expression patterns define unique clusters predictive of cancer phenotype.

Al-Ejeh F, Offenhäuser C, Lim YC, Stringer BW, Day BW, Boyd AW.

Growth Factors. 2014 Dec;32(6):254-64. doi: 10.3109/08977194.2014.984807. Epub 2014 Nov 20. Review.

PMID:
25410964
22.

DataSHIELD: taking the analysis to the data, not the data to the analysis.

Gaye A, Marcon Y, Isaeva J, LaFlamme P, Turner A, Jones EM, Minion J, Boyd AW, Newby CJ, Nuotio ML, Wilson R, Butters O, Murtagh B, Demir I, Doiron D, Giepmans L, Wallace SE, Budin-Ljøsne I, Oliver Schmidt C, Boffetta P, Boniol M, Bota M, Carter KW, deKlerk N, Dibben C, Francis RW, Hiekkalinna T, Hveem K, Kvaløy K, Millar S, Perry IJ, Peters A, Phillips CM, Popham F, Raab G, Reischl E, Sheehan N, Waldenberger M, Perola M, van den Heuvel E, Macleod J, Knoppers BM, Stolk RP, Fortier I, Harris JR, Woffenbuttel BH, Murtagh MJ, Ferretti V, Burton PR.

Int J Epidemiol. 2014 Dec;43(6):1929-44. doi: 10.1093/ije/dyu188. Epub 2014 Sep 26.

23.

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, Marlton P, McLachlan AJ, Kerridge I, Bradstock KF, Kennedy G, Boyd AW, Yeadon TM, Lopez AF, Ramshaw HS, Iland H, Bamford S, Barnden M, DeWitte M, Basser R, Roberts AW.

Leuk Lymphoma. 2015 May;56(5):1406-15. doi: 10.3109/10428194.2014.956316. Epub 2014 Nov 20.

PMID:
25248882
24.

Eph receptors as therapeutic targets in glioblastoma.

Day BW, Stringer BW, Boyd AW.

Br J Cancer. 2014 Sep 23;111(7):1255-61. doi: 10.1038/bjc.2014.73. Epub 2014 Aug 21. Review.

25.

Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells.

Lim YC, Roberts TL, Day BW, Stringer BW, Kozlov S, Fazry S, Bruce ZC, Ensbey KS, Walker DG, Boyd AW, Lavin MF.

Mol Oncol. 2014 Dec;8(8):1603-15. doi: 10.1016/j.molonc.2014.06.012. Epub 2014 Jun 27.

26.

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.

Lickliter JD, Taylor K, Szer J, Grigg A, Arthur C, Hughes TP, Durrant S, Filshie R, Irving I, Seldon M, Ellacott J, Boyd AW, D'Rozario J, Rooney K, Lynch K, Bradstock K; Australasian Leukaemia and Lymphoma Group.

Leuk Lymphoma. 2015 Mar;56(3):630-8. doi: 10.3109/10428194.2014.925547. Epub 2014 Aug 4.

PMID:
24844361
27.

Validating childhood asthma in an epidemiological study using linked electronic patient records.

Cornish RP, Henderson J, Boyd AW, Granell R, Van Staa T, Macleod J.

BMJ Open. 2014 Apr 23;4(4):e005345. doi: 10.1136/bmjopen-2014-005345.

28.

NFIB-mediated repression of the epigenetic factor Ezh2 regulates cortical development.

Piper M, Barry G, Harvey TJ, McLeay R, Smith AG, Harris L, Mason S, Stringer BW, Day BW, Wray NR, Gronostajski RM, Bailey TL, Boyd AW, Richards LJ.

J Neurosci. 2014 Feb 19;34(8):2921-30. doi: 10.1523/JNEUROSCI.2319-13.2014.

29.

Therapeutic targeting of EPH receptors and their ligands.

Boyd AW, Bartlett PF, Lackmann M.

Nat Rev Drug Discov. 2014 Jan;13(1):39-62. doi: 10.1038/nrd4175. Review.

PMID:
24378802
30.
31.

The contribution of head movement to the externalization and internalization of sounds.

Brimijoin WO, Boyd AW, Akeroyd MA.

PLoS One. 2013 Dec 2;8(12):e83068. doi: 10.1371/journal.pone.0083068. eCollection 2013.

32.

Glioma surgical aspirate: a viable source of tumor tissue for experimental research.

Day BW, Stringer BW, Wilson J, Jeffree RL, Jamieson PR, Ensbey KS, Bruce ZC, Inglis P, Allan S, Winter C, Tollesson G, Campbell S, Lucas P, Findlay W, Kadrian D, Johnson D, Robertson T, Johns TG, Bartlett PF, Osborne GW, Boyd AW.

Cancers (Basel). 2013 Apr 3;5(2):357-71. doi: 10.3390/cancers5020357.

33.

The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma.

Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, Tiwari S, Giles KM, Teo C, McDonald KL.

Tumour Biol. 2014 Feb;35(2):1459-65. doi: 10.1007/s13277-013-1200-6. Epub 2013 Sep 26.

PMID:
24068568
34.

Acute delivery of EphA4-Fc improves functional recovery after contusive spinal cord injury in rats.

Spanevello MD, Tajouri SI, Mirciov C, Kurniawan N, Pearse MJ, Fabri LJ, Owczarek CM, Hardy MP, Bradford RA, Ramunno ML, Turnley AM, Ruitenberg MJ, Boyd AW, Bartlett PF.

J Neurotrauma. 2013 Jun 15;30(12):1023-34. doi: 10.1089/neu.2012.2729.

35.

Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia.

Ardjmand A, de Bock CE, Shahrokhi S, Lincz LF, Boyd AW, Burns GF, Thorne RF.

Hematology. 2013 Nov;18(6):315-22. doi: 10.1179/1607845413Y.0000000080. Epub 2013 Feb 20.

PMID:
23433465
36.

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW.

Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.

37.

EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE).

Munro KM, Dixon KJ, Gresle MM, Jonas A, Kemper D, Doherty W, Fabri LJ, Owczarek CM, Pearse M, Boyd AW, Kilpatrick TJ, Butzkueven H, Turnley AM.

PLoS One. 2013;8(2):e55948. doi: 10.1371/journal.pone.0055948. Epub 2013 Feb 4.

38.

Eph/Ephrin signaling in injury and inflammation.

Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, Lackmann M, Boyd AW.

Am J Pathol. 2012 Nov;181(5):1493-503. doi: 10.1016/j.ajpath.2012.06.043. Epub 2012 Sep 25. Review.

39.

Partial change in EphA4 knockout mouse phenotype: loss of diminished GFAP upregulation following spinal cord injury.

Dixon KJ, Munro KM, Boyd AW, Bartlett PF, Turnley AM.

Neurosci Lett. 2012 Sep 6;525(1):66-71. doi: 10.1016/j.neulet.2012.07.023. Epub 2012 Jul 21.

PMID:
22824304
40.

Auditory externalization in hearing-impaired listeners: the effect of pinna cues and number of talkers.

Boyd AW, Whitmer WM, Soraghan JJ, Akeroyd MA.

J Acoust Soc Am. 2012 Mar;131(3):EL268-74. doi: 10.1121/1.3687015.

41.

Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors.

Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, Day BW, Boyd AW, Bastiaens PI, Jørgensen C, Pawson T, Lackmann M.

J Cell Biol. 2011 Dec 12;195(6):1033-45. doi: 10.1083/jcb.201104037. Epub 2011 Dec 5.

42.

The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.

de Bock CE, Ardjmand A, Molloy TJ, Bone SM, Johnstone D, Campbell DM, Shipman KL, Yeadon TM, Holst J, Spanevello MD, Nelmes G, Catchpoole DR, Lincz LF, Boyd AW, Burns GF, Thorne RF.

Leukemia. 2012 May;26(5):918-26. doi: 10.1038/leu.2011.319. Epub 2011 Nov 25.

PMID:
22116550
43.

EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury in mice.

Goldshmit Y, Spanevello MD, Tajouri S, Li L, Rogers F, Pearse M, Galea M, Bartlett PF, Boyd AW, Turnley AM.

PLoS One. 2011;6(9):e24636. doi: 10.1371/journal.pone.0024636. Epub 2011 Sep 13.

44.

Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis.

Herath NI, Spanevello MD, Doecke JD, Smith FM, Pouponnot C, Boyd AW.

Eur J Cancer. 2012 Mar;48(5):753-62. doi: 10.1016/j.ejca.2011.07.003. Epub 2011 Aug 16.

PMID:
21852108
45.

ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.

Day BW, Stringer BW, Spanevello MD, Charmsaz S, Jamieson PR, Ensbey KS, Carter JC, Cox JM, Ellis VJ, Brown CL, Walker DG, Inglis PL, Allan S, Reynolds BA, Lickliter JD, Boyd AW.

Neuro Oncol. 2011 Nov;13(11):1202-12. doi: 10.1093/neuonc/nor119. Epub 2011 Aug 16.

46.

Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products.

Sadeqzadeh E, de Bock CE, Zhang XD, Shipman KL, Scott NM, Song C, Yeadon T, Oliveira CS, Jin B, Hersey P, Boyd AW, Burns GF, Thorne RF.

J Biol Chem. 2011 Aug 12;286(32):28181-91. doi: 10.1074/jbc.M111.234419. Epub 2011 Jun 16.

47.

Activation of ephrin A proteins influences hematopoietic stem cell adhesion and trafficking patterns.

Ting MJ, Day BW, Spanevello MD, Boyd AW.

Exp Hematol. 2010 Nov;38(11):1087-98. doi: 10.1016/j.exphem.2010.07.007. Epub 2010 Jul 23.

PMID:
20655977
48.

Palmitoylation of CD36/FAT regulates the rate of its post-transcriptional processing in the endoplasmic reticulum.

Thorne RF, Ralston KJ, de Bock CE, Mhaidat NM, Zhang XD, Boyd AW, Burns GF.

Biochim Biophys Acta. 2010 Nov;1803(11):1298-307. doi: 10.1016/j.bbamcr.2010.07.002. Epub 2010 Jul 13.

49.

The role of Eph receptors and ephrin ligands in colorectal cancer.

Herath NI, Boyd AW.

Int J Cancer. 2010 May 1;126(9):2003-11. doi: 10.1002/ijc.25147. Review.

50.

Ephrin expression and function in cancer.

McCarron JK, Stringer BW, Day BW, Boyd AW.

Future Oncol. 2010 Jan;6(1):165-76. doi: 10.2217/fon.09.146. Review.

PMID:
20021216

Supplemental Content

Support Center